Multiplex immunofluorescence confirmed that ST6GAL1 protein is significantly upregulated in human disease, with elevated levels detected as early as stage I. To test whether this enzyme is a promoter of pancreatic cancer, we created a pancreas-specific genetic deletion of ST6GAL1 in the KC mouse model (ST6GAL1flx/flx;p48Cre; LSLKRASG12D [ST6KC]). Here, ST6GAL1 is linked to familial pancreatic carcinoma.